Akki you are twisting around and around but you don’t give me (us share holders) a straight answer.
Why are you here following PER how do you see this company now and where do you think it will go considering the present management and the few (if any in your opinion) boxes ticked so far, the overall situation of drug’s pipeline and how good in your opinion is the ATL1102 status. It shouldn’t be a problem to enlight us all with a simple comment considering you claim to be a shareholder. We wait.
Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-140
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
-0.001(10.0%) |
Mkt cap ! $9.786M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.0¢ | 0.9¢ | $94.66K | 10.09M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 661860 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 1588275 | 6 |
View Market Depth
| Last trade - 15.52pm 27/06/2025 (20 minute delay) ? |
| PER (ASX) Chart |